{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:21:09Z","timestamp":1787610069367,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"35","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI144115"],"award-info":[{"award-number":["R01 AI144115"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL178459"],"award-info":[{"award-number":["R01HL178459"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["25PRE1373953"],"award-info":[{"award-number":["25PRE1373953"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["AHA-TPA-971237"],"award-info":[{"award-number":["AHA-TPA-971237"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["25TPA1473648"],"award-info":[{"award-number":["25TPA1473648"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cutaneous melanoma remains the most lethal skin cancer due to profound tumor heterogeneity and the frequent development of resistance to current therapies. Here, we identify the cysteinyl leukotriene receptor 1 (CysLT\n                    <jats:sub>1<\/jats:sub>\n                    R) as a previously unrecognized driver of melanoma progression. Analysis of bulk RNA-sequencing datasets from The Cancer Genome Atlas (TCGA) revealed significantly elevated CysLT\n                    <jats:sub>1<\/jats:sub>\n                    R transcript in metastatic tumors compared to primary tumors. Functional studies in murine and human melanoma cells demonstrated that leukotriene D\n                    <jats:sub>4<\/jats:sub>\n                    (LTD\n                    <jats:sub>4<\/jats:sub>\n                    )-mediated activation of CysLT\n                    <jats:sub>1<\/jats:sub>\n                    R promotes melanoma cell proliferation and invasion through the parallel engagement of YAP and ERK signaling pathways. Notably, melanoma cells express LTC\n                    <jats:sub>4<\/jats:sub>\n                    synthase and secrete cysteinyl leukotrienes, establishing a constitutive autocrine signaling loop that sustains CysLT\n                    <jats:sub>1<\/jats:sub>\n                    R activity independently of the host niche. Genetic ablation or pharmacological inhibition of CysLT\n                    <jats:sub>1<\/jats:sub>\n                    R with MK571 significantly attenuated tumor growth in vivo and was associated with inhibition of the YAP-LOXL-2 signaling axis. In addition, studies using\n                    <jats:italic>Cysltr1<\/jats:italic>\n                    <jats:sup>\u2013\/\u2013<\/jats:sup>\n                    mice reveal that host-derived CysLT\n                    <jats:sub>1<\/jats:sub>\n                    R signaling within the tumor microenvironment also contributes to melanoma progression. Together, these findings uncover a previously unrecognized pro-tumorigenic CysLT\n                    <jats:sub>1<\/jats:sub>\n                    R-ERK\/YAP,LOXL-2 signaling circuit that promotes cutaneous melanoma progression and highlight CysLT\n                    <jats:sub>1<\/jats:sub>\n                    R as a potential therapeutic target for melanoma.\n                  <\/jats:p>","DOI":"10.1038\/s41388-026-03919-1","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T18:55:02Z","timestamp":1784919302000},"page":"3673-3683","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Autocrine CysLT1R-ERK\/YAP signaling drives melanoma progression and reveals a targetable oncogenic GPCR axis"],"prefix":"10.1038","volume":"45","author":[{"given":"Emma Elizabeth","family":"Sabu Kattuman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7725-8294","authenticated-orcid":false,"given":"Lakshminarayan Reddy","family":"Teegala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatesh","family":"Katari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somayeh","family":"Darzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8147-4379","authenticated-orcid":false,"given":"Srinivas Vinod","family":"Saladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"de la Serna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles K.","family":"Thodeti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2377-4327","authenticated-orcid":false,"given":"Sailaja","family":"Paruchuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"3919_CR1","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1615\/CritRevEukaryotGeneExpr.2020028454","volume":"30","author":"B Ahmed","year":"2020","unstructured":"Ahmed B, Qadir MI, Ghafoor S. Malignant melanoma: skin cancer-diagnosis, prevention, and treatment. Crit Rev Eukaryot Gene Expr. 2020;30:291\u20137.","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"3919_CR2","doi-asserted-by":"publisher","first-page":"adv00139","DOI":"10.2340\/00015555-3494","volume":"100","author":"JU Bertrand","year":"2020","unstructured":"Bertrand JU, Steingrimsson E, Jouenne F, Bressac-de Paillerets B, Larue L. Melanoma risk and melanocyte biology. Acta Derm Venereol. 2020;100:adv00139.","journal-title":"Acta Derm Venereol"},{"key":"3919_CR3","doi-asserted-by":"crossref","unstructured":"Kalantri S, Pachika P, Jones T, Kong M, Kloecker G, Chesney J. Survival outcomes in stage III to IV melanoma before and after the immunotherapy era: persistent racial and socioeconomic disparities. JCO Oncol Pract. 2025;0:OP-25-00433.","DOI":"10.1200\/OP-25-00433"},{"key":"3919_CR4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.4103\/aam.aam_56_18","volume":"18","author":"N Singh","year":"2019","unstructured":"Singh N, Baby D, Rajguru JP, Patil PB, Thakkannavar SS, Pujari VB. Inflammation and cancer. Ann Afr Med. 2019;18:121\u20136.","journal-title":"Ann Afr Med"},{"key":"3919_CR5","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature01322","volume":"420","author":"LM Coussens","year":"2002","unstructured":"Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860\u20137.","journal-title":"Nature"},{"key":"3919_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1006\/pupt.2000.0262","volume":"14","author":"S Nicosia","year":"2001","unstructured":"Nicosia S, Capra V, Rovati GE. Leukotrienes as mediators of asthma. Pulm Pharm Ther. 2001;14:3\u201319.","journal-title":"Pulm Pharm Ther"},{"key":"3919_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/cph4.70022","volume":"15","author":"EE Sabu Kattuman","year":"2025","unstructured":"Sabu Kattuman EE, Teegala LR, Darzi S, Thodeti CK, Paruchuri S. Leukotrienes: bridging the inflammatory gap in asthma and inflammatory bowel diseases (IBD). Compr Physiol. 2025;15:e70022.","journal-title":"Compr Physiol"},{"key":"3919_CR8","doi-asserted-by":"publisher","first-page":"10967","DOI":"10.1074\/jbc.C113.453704","volume":"288","author":"Y Kanaoka","year":"2013","unstructured":"Kanaoka Y, Maekawa A, Austen KF. Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand. J Biol Chem. 2013;288:10967\u201372.","journal-title":"J Biol Chem"},{"key":"3919_CR9","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/21658","volume":"399","author":"KR Lynch","year":"1999","unstructured":"Lynch KR, O\u2019Neill GP, Liu Q, Im DS, Sawyer N, Metters KM, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature. 1999;399:789\u201393.","journal-title":"Nature"},{"key":"3919_CR10","doi-asserted-by":"publisher","first-page":"30531","DOI":"10.1074\/jbc.M003490200","volume":"275","author":"CE Heise","year":"2000","unstructured":"Heise CE, O\u2019Dowd BF, Figueroa DJ, Sawyer N, Nguyen T, Im DS, et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem. 2000;275:30531\u20136.","journal-title":"J Biol Chem"},{"key":"3919_CR11","doi-asserted-by":"publisher","first-page":"12221","DOI":"10.3390\/ijms232012221","volume":"23","author":"L Saier","year":"2022","unstructured":"Saier L, Ribeiro J, Daunizeau T, Houssin A, Ichim G, Barette C, et al. Blockade of platelet CysLT1R receptor with Zafirlukast counteracts platelet protumoral action and prevents breast cancer metastasis to bone and lung. Int J Mol Sci. 2022;23:12221.","journal-title":"Int J Mol Sci"},{"key":"3919_CR12","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.3390\/cancers12102950","volume":"12","author":"K Slater","year":"2020","unstructured":"Slater K, Heeran AB, Garcia-Mulero S, Kalirai H, Sanz-Pamplona R, Rahman A, et al. High cysteinyl leukotriene receptor 1 expression correlates with poor survival of uveal melanoma patients, and cognate antagonist drugs modulate the growth, cancer secretome, and metabolism of uveal melanoma cells. Cancers. 2020;12:2950.","journal-title":"Cancers"},{"key":"3919_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2024.110120","volume":"248","author":"P Garcia de Alba Graue","year":"2024","unstructured":"Garcia de Alba Graue P, Abdouh M, Goyeneche A, Burnier JV, Burnier MN. CYSLTR1 antagonism displays potent anti-tumor effects in uveal melanoma. Exp Eye Res. 2024;248:110120.","journal-title":"Exp Eye Res"},{"key":"3919_CR14","doi-asserted-by":"publisher","first-page":"13538","DOI":"10.1074\/jbc.M409811200","volume":"280","author":"S Paruchuri","year":"2005","unstructured":"Paruchuri S, Broom O, Dib K, Sjolander A. The pro-inflammatory mediator leukotriene D4 induces phosphatidylinositol 3-kinase and Rac-dependent migration of intestinal epithelial cells. J Biol Chem. 2005;280:13538\u201344.","journal-title":"J Biol Chem"},{"key":"3919_CR15","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1242\/jcs.115.9.1883","volume":"115","author":"S Paruchuri","year":"2002","unstructured":"Paruchuri S, Hallberg B, Juhas M, Larsson C, Sjolander A. Leukotriene D(4) activates MAPK through a Ras-independent but PKCepsilon-dependent pathway in intestinal epithelial cells. J Cell Sci. 2002;115:1883\u201393.","journal-title":"J Cell Sci"},{"key":"3919_CR16","doi-asserted-by":"publisher","first-page":"45577","DOI":"10.1074\/jbc.M302881200","volume":"278","author":"S Paruchuri","year":"2003","unstructured":"Paruchuri S, Sjolander A. Leukotriene D4 mediates survival and proliferation via separate but parallel pathways in the human intestinal epithelial cell line Int 407. J Biol Chem. 2003;278:45577\u201385.","journal-title":"J Biol Chem"},{"key":"3919_CR17","doi-asserted-by":"publisher","first-page":"16477","DOI":"10.1074\/jbc.M705822200","volume":"283","author":"S Paruchuri","year":"2008","unstructured":"Paruchuri S, Jiang Y, Feng C, Francis SA, Plutzky J, Boyce JA. Leukotriene E4 activates peroxisome proliferator-activated receptor gamma and induces prostaglandin D2 generation by human mast cells. J Biol Chem. 2008;283:16477\u201387.","journal-title":"J Biol Chem"},{"key":"3919_CR18","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.cardiores.2007.05.018","volume":"76","author":"Y Kaetsu","year":"2007","unstructured":"Kaetsu Y, Yamamoto Y, Sugihara S, Matsuura T, Igawa G, Matsubara K, et al. Role of cysteinyl leukotrienes in the proliferation and the migration of murine vascular smooth muscle cells in vivo and in vitro. Cardiovasc Res. 2007;76:160\u20136.","journal-title":"Cardiovasc Res"},{"key":"3919_CR19","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/icb.2014.104","volume":"93","author":"W Lee","year":"2015","unstructured":"Lee W, Su Kim H, Lee GR. Leukotrienes induce the migration of Th17 cells. Immunol Cell Biol. 2015;93:472\u20139.","journal-title":"Immunol Cell Biol"},{"key":"3919_CR20","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.2174\/1389201024666221207143513","volume":"24","author":"Y Chen","year":"2023","unstructured":"Chen Y, Zhang J, Wei S. Montelukast inhibits lung cancer cell migration by suppressing cysteinyl leukotriene receptor 1 expression in vitro. Curr Pharm Biotechnol. 2023;24:1335\u201342.","journal-title":"Curr Pharm Biotechnol"},{"key":"3919_CR21","first-page":"99","volume":"18","author":"M Matsuyama","year":"2007","unstructured":"Matsuyama M, Hayama T, Funao K, Kawahito Y, Sano H, Takemoto Y, et al. Overexpression of cysteinyl LT1 receptor in prostate cancer and CysLT1R antagonist inhibits prostate cancer cell growth through apoptosis. Oncol Rep. 2007;18:99\u2013104.","journal-title":"Oncol Rep"},{"key":"3919_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01157-6","volume":"21","author":"SR Satapathy","year":"2023","unstructured":"Satapathy SR, Ghatak S, Sjolander A. The tumor promoter cysteinyl leukotriene receptor 1 regulates PD-L1 expression in colon cancer cells via the Wnt\/beta-catenin signaling axis. Cell Commun Signal. 2023;21:138.","journal-title":"Cell Commun Signal"},{"key":"3919_CR23","doi-asserted-by":"publisher","first-page":"20820","DOI":"10.1074\/jbc.M203163200","volume":"277","author":"A Maekawa","year":"2002","unstructured":"Maekawa A, Austen KF, Kanaoka Y. Targeted gene disruption reveals the role of cysteinyl leukotriene 1 receptor in the enhanced vascular permeability of mice undergoing acute inflammatory responses. J Biol Chem. 2002;277:20820\u20134.","journal-title":"J Biol Chem"},{"key":"3919_CR24","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1111\/jcmm.17924","volume":"27","author":"R Gudneppanavar","year":"2023","unstructured":"Gudneppanavar R, Sabu Kattuman EE, Teegala LR, Southard E, Tummala R, Joe B, et al. Epigenetic histone modification by butyrate downregulates KIT and attenuates mast cell function. J Cell Mol Med. 2023;27:2983\u201394.","journal-title":"J Cell Mol Med"},{"key":"3919_CR25","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas N. Genomic classification of cutaneous melanoma. Cell. 2015;161:1681\u201396.","DOI":"10.1016\/j.cell.2015.05.044"},{"key":"3919_CR26","doi-asserted-by":"publisher","first-page":"5846","DOI":"10.1158\/0008-5472.CAN-16-3152","volume":"77","author":"F Salvador","year":"2017","unstructured":"Salvador F, Mart\u00edn A, L\u00f3pez-Men\u00e9ndez C, Moreno-Bueno G, Santos V, V\u00e1zquez-Naharro A, et al. Lysyl oxidase-like protein LOXL2 promotes lung metastasis of breast cancer. Cancer Res. 2017;77:5846\u201359.","journal-title":"Cancer Res"},{"key":"3919_CR27","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s12672-024-01107-9","volume":"15","author":"C Ye","year":"2024","unstructured":"Ye C, Jiang SH, Zeng TL, He SH, Cao JJ, Xiao JR. The role of LOXL2 in tumor progression, immune response and cellular senescence: a comprehensive analysis. Discov Oncol. 2024;15:245.","journal-title":"Discov Oncol"},{"key":"3919_CR28","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1101\/gad.1909210","volume":"24","author":"B Zhao","year":"2010","unstructured":"Zhao B, Li L, Lei Q, Guan KL. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev. 2010;24:862\u201374.","journal-title":"Genes Dev"},{"key":"3919_CR29","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41417-022-00531-9","volume":"30","author":"H Weisser","year":"2023","unstructured":"Weisser H, Gobel T, Melissa Krishnathas G, Kreiss M, Angioni C, Surun D, et al. Knock-out of 5-lipoxygenase in overexpressing tumor cells: consequences on gene expression and cellular function. Cancer Gene Ther. 2023;30:108\u201323.","journal-title":"Cancer Gene Ther"},{"key":"3919_CR30","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1038\/sj.onc.1210407","volume":"26","author":"ZG Goldsmith","year":"2007","unstructured":"Goldsmith ZG, Dhanasekaran DN. G protein regulation of MAPK networks. Oncogene. 2007;26:3122\u201342.","journal-title":"Oncogene"},{"key":"3919_CR31","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ccr.2014.04.016","volume":"25","author":"X Feng","year":"2014","unstructured":"Feng X, Degese MS, Iglesias-Bartolome R, Vaque JP, Molinolo AA, Rodrigues M, et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated Rho GTPase signaling circuitry. Cancer cell. 2014;25:831\u201345.","journal-title":"Cancer cell"},{"key":"3919_CR32","doi-asserted-by":"publisher","first-page":"115015","DOI":"10.1016\/j.biopha.2023.115015","volume":"164","author":"M Nigam","year":"2023","unstructured":"Nigam M, Mishra AP, Deb VK, Dimri DB, Tiwari V, Bungau SG, et al. Evaluation of the association of chronic inflammation and cancer: insights and implications. Biomed Pharmacother. 2023;164:115015.","journal-title":"Biomed Pharmacother"},{"key":"3919_CR33","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/ACI.0b013e32833489c3","volume":"10","author":"TS Hallstrand","year":"2010","unstructured":"Hallstrand TS, Henderson WR Jr. An update on the role of leukotrienes in asthma. Curr Opin Allergy Clin Immunol. 2010;10:60\u20136.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"3919_CR34","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1067\/mai.2003.25","volume":"111","author":"ST Holgate","year":"2003","unstructured":"Holgate ST, Peters-Golden M, Panettieri RA, Henderson WR Jr. Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J Allergy Clin Immunol. 2003;111:S18\u201334. discussion S34-16.","journal-title":"J Allergy Clin Immunol"},{"key":"3919_CR35","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1073\/pnas.1817325115","volume":"116","author":"E Duah","year":"2019","unstructured":"Duah E, Teegala LR, Kondeti V, Adapala RK, Keshamouni VG, Kanaoka Y, et al. Cysteinyl leukotriene 2 receptor promotes endothelial permeability, tumor angiogenesis, and metastasis. Proc Natl Acad Sci USA 2019;116:199\u2013204.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3919_CR36","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.canlet.2020.05.023","volume":"488","author":"SR Satapathy","year":"2020","unstructured":"Satapathy SR, Sjolander A. Cysteinyl leukotriene receptor 1 promotes 5-fluorouracil resistance and resistance-derived stemness in colon cancer cells. Cancer Lett. 2020;488:50\u201362.","journal-title":"Cancer Lett"},{"key":"3919_CR37","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s10571-017-0507-z","volume":"38","author":"P Piromkraipak","year":"2018","unstructured":"Piromkraipak P, Sangpairoj K, Tirakotai W, Chaithirayanon K, Unchern S, Supavilai P, et al. Cysteinyl leukotriene receptor antagonists inhibit migration, invasion, and expression of MMP-2\/9 in human glioblastoma. Cell Mol Neurobiol. 2018;38:559\u201373.","journal-title":"Cell Mol Neurobiol"},{"key":"3919_CR38","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3816\/CLM.2008.n.049","volume":"8","author":"F Schain","year":"2008","unstructured":"Schain F, Schain D, Mahshid Y, Liu C, Porwit A, Xu D, et al. Differential expression of cysteinyl leukotriene receptor 1 and 15-lipoxygenase-1 in non-Hodgkin lymphomas. Clin Lymphoma Myeloma. 2008;8:340\u20137.","journal-title":"Clin Lymphoma Myeloma"},{"key":"3919_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/srep03274","volume":"3","author":"E Duah","year":"2013","unstructured":"Duah E, Adapala RK, Al-Azzam N, Kondeti V, Gombedza F, Thodeti CK, et al. Cysteinyl leukotrienes regulate endothelial cell inflammatory and proliferative signals through CysLT(2) and CysLT(1) receptors. Sci Rep. 2013;3:3274.","journal-title":"Sci Rep"},{"key":"3919_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1545952","volume":"15","author":"L Zhang","year":"2025","unstructured":"Zhang L, Zhang F, Liang H, Qin X, Mo Y, Chen S, et al. Hippo\/YAP signaling pathway in colorectal cancer: regulatory mechanisms and potential drug exploration. Front Oncol. 2025;15:1545952.","journal-title":"Front Oncol"},{"key":"3919_CR41","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.3390\/cancers15194701","volume":"15","author":"HL Thrash","year":"2023","unstructured":"Thrash HL, Pendergast AM. Multi-functional regulation by YAP\/TAZ signaling networks in tumor progression and metastasis. Cancers. 2023;15:4701.","journal-title":"Cancers"},{"key":"3919_CR42","doi-asserted-by":"publisher","first-page":"4357","DOI":"10.18632\/oncotarget.2974","volume":"6","author":"B You","year":"2015","unstructured":"You B, Yang YL, Xu ZD, Dai YY, Liu S, Mao JH, et al. Inhibition of ERK1\/2 down-regulates the Hippo\/YAP signaling pathway in human NSCLC cells. Oncotarget. 2015;6:4357\u201368.","journal-title":"Oncotarget"},{"key":"3919_CR43","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0002-9440(10)64198-3","volume":"161","author":"R Hennig","year":"2002","unstructured":"Hennig R, Ding XZ, Tong WG, Schneider MB, Standop J, Friess H, et al. 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am J Pathol. 2002;161:421\u20138.","journal-title":"Am J Pathol"},{"key":"3919_CR44","doi-asserted-by":"publisher","first-page":"6525","DOI":"10.1158\/1078-0432.CCR-07-4631","volume":"14","author":"LG Melstrom","year":"2008","unstructured":"Melstrom LG, Bentrem DJ, Salabat MR, Kennedy TJ, Ding XZ, Strouch M, et al. Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model. Clin Cancer Res: Off J Am Assoc Cancer Res. 2008;14:6525\u201330.","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"3919_CR45","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.4049\/jimmunol.1201920","volume":"190","author":"K Wejksza","year":"2013","unstructured":"Wejksza K, Lee-Chang C, Bodogai M, Bonzo J, Gonzalez FJ, Lehrmann E, et al. Cancer-produced metabolites of 5-lipoxygenase induce tumor-evoked regulatory B cells via peroxisome proliferator-activated receptor alpha. J Immunol. 2013;190:2575\u201384.","journal-title":"J Immunol"},{"key":"3919_CR46","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.3389\/fphar.2020.01289","volume":"11","author":"W Tian","year":"2020","unstructured":"Tian W, Jiang X, Kim D, Guan T, Nicolls MR, Rockson SG. Leukotrienes in tumor-associated inflammation. Front Pharmacol. 2020;11:1289.","journal-title":"Front Pharmacol"},{"key":"3919_CR47","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrc2809","volume":"10","author":"D Wang","year":"2010","unstructured":"Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer. 2010;10:181\u201393.","journal-title":"Nat Rev Cancer"},{"key":"3919_CR48","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1126\/science.aad0501","volume":"352","author":"I Tirosh","year":"2016","unstructured":"Tirosh I, Izar B, Prakadan SM, Wadsworth MH 2nd, Treacy D, Trombetta JJ, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016;352:189\u201396.","journal-title":"Science"},{"key":"3919_CR49","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1016\/j.rmed.2006.02.026","volume":"100","author":"JC Virchow","year":"2006","unstructured":"Virchow JC, Bachert C. Efficacy and safety of montelukast in adults with asthma and allergic rhinitis. Respir Med. 2006;100:1952\u20139.","journal-title":"Respir Med"},{"key":"3919_CR50","first-page":"346","volume":"20","author":"AJ Olszanski","year":"2014","unstructured":"Olszanski AJ. Current and future roles of targeted therapy and immunotherapy in advanced melanoma. J Manag Care Spec Pharm. 2014;20:346\u201356.","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03919-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03919-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03919-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:03:10Z","timestamp":1787608990000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03919-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":50,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2026,9,15]]}},"alternative-id":["3919"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03919-1","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"16 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}